<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; REAL</title>
	<atom:link href="http://www.tapanray.in/tag/real/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>&#8216;Indian Pharma’s Apathy Towards Digital Marketing’ &#8211; A Misgiving Or Real?</title>
		<link>http://www.tapanray.in/indian-pharmas-apathy-towards-digital-marketing-a-misgiving-or-real/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-pharmas-apathy-towards-digital-marketing-a-misgiving-or-real</link>
		<comments>http://www.tapanray.in/indian-pharmas-apathy-towards-digital-marketing-a-misgiving-or-real/#comments</comments>
		<pubDate>Fri, 02 Jun 2023 06:18:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[apathy]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[misgiving]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[REAL]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tools]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10794</guid>
		<description><![CDATA[As I gather from different sources, an increasing number of Indian pharma companies are increasingly embracing digitalization in their marketing operations, especially after the crippling experience during the Covid lockdown period. They realize the use of digital platforms would be a great &#8230; <a href="http://www.tapanray.in/indian-pharmas-apathy-towards-digital-marketing-a-misgiving-or-real/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-pharmas-apathy-towards-digital-marketing-a-misgiving-or-real/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Expensive Is Drug Innovation?</title>
		<link>http://www.tapanray.in/how-expensive-is-drug-innovation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-expensive-is-drug-innovation</link>
		<comments>http://www.tapanray.in/how-expensive-is-drug-innovation/#comments</comments>
		<pubDate>Mon, 16 May 2016 00:00:46 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affairs]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[goods]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Internal]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[REAL]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tufts Centre]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7637</guid>
		<description><![CDATA[High prices for patented drugs are quite often attributed to the exorbitant cost of drug innovation, by the global pharma players. This argument is played, replayed again, again… and again by them, in various ways and forms, especially when many &#8230; <a href="http://www.tapanray.in/how-expensive-is-drug-innovation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-expensive-is-drug-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Access to Medicine: Losing Track in Cacophony</title>
		<link>http://www.tapanray.in/access-to-medicine-losing-track-in-cacophony/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=access-to-medicine-losing-track-in-cacophony</link>
		<comments>http://www.tapanray.in/access-to-medicine-losing-track-in-cacophony/#comments</comments>
		<pubDate>Mon, 30 Dec 2013 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2004]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[ASSOCHAM]]></category>
		<category><![CDATA[back]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[cacophony]]></category>
		<category><![CDATA[calculation]]></category>
		<category><![CDATA[consulting]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[debate]]></category>
		<category><![CDATA[Dinosaurian]]></category>
		<category><![CDATA[direction]]></category>
		<category><![CDATA[drowns]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[envelope]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[facilities]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indicators]]></category>
		<category><![CDATA[losing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[millennium]]></category>
		<category><![CDATA[Modern]]></category>
		<category><![CDATA[number]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[per capita]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[REAL]]></category>
		<category><![CDATA[reality]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[situation]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4467</guid>
		<description><![CDATA[Indian Healthcare space is by and large an arena, where perceptions prevail over the changing reality in many important areas. Consequently, fierce discourse in those areas mostly gives rise to a cacophony of ‘Your Perceptions Against Mine’. It is intriguing, why even &#8230; <a href="http://www.tapanray.in/access-to-medicine-losing-track-in-cacophony/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/access-to-medicine-losing-track-in-cacophony/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India and China&#8230;Practical relevance of &#8216;Priority Watch List (PWL)&#8217; status in ‘Special 301 Reports’ of America&#8230;and the REAL ‘Game Changers’</title>
		<link>http://www.tapanray.in/india-and-china-practical-relevance-of-priority-watch-list-pwl-status-in-special-301-reports-of-america-and-the-real-game-changers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-and-china-practical-relevance-of-priority-watch-list-pwl-status-in-special-301-reports-of-america-and-the-real-game-changers</link>
		<comments>http://www.tapanray.in/india-and-china-practical-relevance-of-priority-watch-list-pwl-status-in-special-301-reports-of-america-and-the-real-game-changers/#comments</comments>
		<pubDate>Mon, 10 May 2010 00:30:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Changers]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practical]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[PWL]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[REAL]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[Reports]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[status]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Watch]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=430</guid>
		<description><![CDATA[Many stakeholders around the world believe that Intellectual Property Rights (IPR) environment in China is far better than what we have in India. Interestingly “2010 Special 301 Report” of the United States of America dated April 30, 2010, paints a &#8230; <a href="http://www.tapanray.in/india-and-china-practical-relevance-of-priority-watch-list-pwl-status-in-special-301-reports-of-america-and-the-real-game-changers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-and-china-practical-relevance-of-priority-watch-list-pwl-status-in-special-301-reports-of-america-and-the-real-game-changers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
